Glioblastoma, the most lethal primary brain tumor, presents a profoundly immunosuppressive microenvironment that limits therapeutic efficacy. This comprehensive review examines emerging strategies to reprogram the glioblastoma microenvironment and restore antitumor immunity. The research evaluates novel small molecules, natural products, adjuvants, and nanomedicine platforms targeting immunosuppression. Key therapeutic approaches include disrupting cancer-associated fibroblasts (CAFs), reprogramming macrophages using CSF-1 inhibitors or TLR agonists, depleting myeloid cells through chemokine receptor blockade, and reversing metabolic suppression. Preclinical studies demonstrate that these modalities induce immunogenic cell death and regulate checkpoint molecules while inhibiting immunosuppressive signaling through STAT3 and NF-κB pathways. Nanocomplexes enhance brain delivery and enable multimodal drug co-delivery. However, checkpoint inhibitors have shown disappointing results in phase III clinical trials, and myeloid-targeted agents face limitations due to microenvironment plasticity. The review concludes that effective glioblastoma immunotherapy requires rationally designed multimodal combinations simultaneously targeting stromal barriers, immunosuppressive factors, and T cell exhaustion, with oncolytic viruses and biomarker-guided adaptive designs showing promise for future clinical development.

Adoptive cell therapies represent a promising frontier in cancer treatment, particularly for solid tumors where traditional approaches have shown limitations. This comprehensive review examines emerging innovations and engineering strategies driving clinical translation in this field. Researchers have developed advanced techniques to enhance cell therapy efficacy, including genetic engineering modifications, novel manufacturing processes, and refined patient selection criteria. Key developments encompass improved CAR-T cell designs, enhanced tumor-infiltrating lymphocyte processing, and next-generation cell expansion protocols. Clinical trials have demonstrated measurable improvements in response rates and patient outcomes across multiple solid tumor types. The significance of these advances lies in their potential to overcome previous barriers to solid tumor treatment, offering patients with limited options new therapeutic pathways. As engineering strategies continue evolving and more clinical data accumulates, adoptive cell therapies are transitioning from experimental approaches to viable treatment options, fundamentally reshaping oncology practice and expanding treatment possibilities for previously intractable malignancies.

Glioblastoma remains one of the most aggressive and treatment-resistant brain cancers, with poor survival rates despite multimodal therapy. The blood–brain barrier, tumor heterogeneity, and diffuse infiltration significantly impede drug delivery and therapeutic efficacy. Phytochemicals including curcumin, resveratrol, and quercetin demonstrate promising antiproliferative, proapoptotic, antiinflammatory, and antiangiogenic properties. However, their clinical application is severely limited by poor aqueous solubility, rapid metabolism, low bioavailability, chemical instability, and inadequate brain penetration. Nanoparticle-based delivery systems present a rational approach to overcome these challenges by improving phytochemical stability and solubility, enabling controlled release, facilitating receptor-mediated blood–brain barrier transport, and enhancing intracellular accumulation in glioblastoma cells. This comprehensive review examines the molecular mechanisms and therapeutic potential of phytochemical-based nanoparticles alongside available in vitro, in vivo, and emerging clinical evidence. Significant barriers to clinical translation remain, including manufacturing scalability, reproducibility, long-term safety concerns, regulatory uncertainty, and the need to demonstrate intratumoral delivery. Current evidence suggests phytochemical nanomedicines function best as adjuncts to standard therapy rather than standalone treatments, with greatest translational potential in combination strategies that integrate improved drug delivery with multitarget molecular modulation.

Glioblastoma remains one of the most lethal brain cancers, with median patient survival stagnating at approximately 15 months despite decades of research. The disease's resistance to treatment stems from its complex molecular landscape and the impracticality of combining multiple drugs due to compounded toxicity. Researchers led by Dr. Roger Abounader at UVA Comprehensive Cancer Center have developed an innovative microRNA-based therapeutic approach targeting multiple cancer-promoting pathways simultaneously. Through systematic screening, they identified three key microRNAs—miR-340 and miR-382 as tumor suppressors, and miR-17 as an oncogenic driver. Testing in both established glioblastoma cell lines and patient-derived stem cell lines demonstrated that modulating these miRNAs significantly reduced cell proliferation, invasion, and self-renewal capacity. Notably, in vivo mouse studies confirmed the antitumor effects observed in cellular models. The researchers employed nanoparticles combined with focused ultrasound to enhance blood-brain barrier penetration and therapeutic delivery. This multitarget miRNA strategy represents a critical advancement toward clinical trials and offers a promising alternative to traditional polypharmacy approaches in glioblastoma treatment.

Cancer remains one of the most threatening diseases of this century, causing approximately eight million deaths annually worldwide. The disease's complexity demands innovative approaches and translation of scientific knowledge into new therapeutics and treatment strategies. A cross-border consortium led by Maastricht University, including Antwerp University, VIB, Basic Pharma Technologies, and MosaMedix, addresses specific challenges in skin cancer treatment. Funded by the Interreg V Flanders-Netherlands program and European Regional Development Fund (EFRO), the SKiN-HUID project develops a novel skin cancer treatment based on an Anx-A5 platform for targeted drug delivery. The approach employs electrical or hyperthermic stimulation to trigger cellular stress, enabling efficient, precise medication delivery at reduced doses. This minimizes systemic side effects while maintaining patient quality of life. The consortium combines complementary expertise: Prof. Chris Marine's VIB laboratory provides melanoma expertise, Prof. John-Paul Bogers' team contributes biomedical microscopy and toxicological analysis with leading hyperthermia research, and Prof. Chris Reutelingsperger's laboratory offers unique annexine biochemistry knowledge. Basic Pharma and MosaMedix provide GMP production development and pharmaceutical formulation capabilities, advancing the technology toward preclinical and clinical validation.

# Summary This comprehensive review examines glioblastoma as a complex, evolving tumor ecosystem, bridging molecular understanding with clinical therapeutic applications. Published in Experimental Hematology & Oncology in October 2026, the open-access article synthesizes current knowledge of glioblastoma's molecular alterations and their translation into treatment strategies. The review explores how glioblastoma functions as a dynamic system where multiple molecular pathways interact within the tumor microenvironment, involving interactions between cancer cells, immune components, and stromal elements. By analyzing genetic mutations, epigenetic changes, and signaling cascades characteristic of glioblastoma, the authors connect fundamental molecular discoveries to emerging therapeutic approaches. This integrated perspective is critical for advancing treatment efficacy, as understanding glioblastoma's ecosystem nature helps explain treatment resistance and tumor heterogeneity. The review emphasizes why personalized, ecosystem-informed therapeutic strategies are necessary to improve outcomes for this aggressive brain cancer, ultimately providing valuable insights for oncologists and researchers developing next-generation glioblastoma interventions.

This narrative review, authored by researchers at Xiamen-based institutions, synthesizes current understanding of neuroimmune communication within the central nervous system, particularly in the context of glioblastoma pathogenesis. The study examines bidirectional signaling between neurons, glial cells (astrocytes and microglia), and immune cells mediated through shared receptors, ligands, and secreted molecules. The review systematically analyzes five interconnected axes: the receptor-ligand repertoires of CNS-resident cells; neural inputs to glioblastoma and reciprocal tumor signals; remodeling of glial cells and glioma-associated macrophages and microglia; innate and adaptive immune suppression mechanisms, including a "chemical-cellular" suppressive architecture; and blood-brain barrier constraints on immune infiltration. Glioblastoma is identified as particularly adept at co-opting neuroimmune networks to establish an immunosuppressive tumor microenvironment. The review identifies emerging therapeutic opportunities targeting each mechanistic layer while acknowledging significant unanswered questions in neuroimmunology. By clarifying how nervous and immune system interactions contribute to neurological disorders, this work provides crucial insights for developing future therapeutic interventions targeting the complex interplay between neural, immune, and tumor compartments.

Dendritic cells function as scouts within the immune system, patrolling tissues and lymph nodes to identify foreign threats and present them to T cells, which then mount targeted attacks. These specialized white blood cells are considered the body's most powerful antigen-presenting cells, bridging innate and adaptive immunity. In cancer patients, this system fails because dendritic cells become dysfunctional and the immune system tolerates malignant cells rather than attacking them. Dendritic cell therapy aims to restore this protective mechanism through a complex, multi-step process offered only at specialized centers. Treatment begins with leukapheresis to isolate white blood cells, from which immature dendritic cells are extracted and cultured in laboratories. The cells are then exposed to cancer-specific material—either tumor lysate from biopsies, cancer-associated proteins, or neoantigens identified through genetic sequencing of the patient's tumor. After maturation and activation, these trained dendritic cells are reinfused as a series of injections over weeks or months. Once reintroduced, the cells migrate to lymph nodes and present cancer signatures to T cells, generating personalized immune responses. This personalized approach represents a significant advancement in cancer immunotherapy by leveraging the body's native immune machinery to combat individual patient tumors.

Northwest Biotherapeutics, a Bethesda-based biotech firm, announced a collaboration with the UK's National Health Service Blood and Transplant (NHSBT) to support production of DCVax®-L, its personalized dendritic cell-based cancer vaccine. This partnership, formalized in October 2026, leverages NHSBT's advanced therapy expertise and facilities to enhance manufacturing scalability and accessibility. DCVax®-L is being developed for glioblastoma, the most aggressive form of primary brain cancer, with each dose customized for individual patients using their own immune cells. The collaboration initially involves NHSBT sites in Leeds and Oxford, with plans for phased expansion across England's ten therapeutic apheresis units. Northwest Biotherapeutics completed a 331-patient Phase III trial with results published in JAMA Oncology and has submitted a marketing authorization application currently under regulatory review in the UK. The company also developed DCVax®-Direct for inoperable solid tumors. This partnership significantly strengthens infrastructure for manufacturing advanced personalized therapies in the UK, potentially improving patient access to cutting-edge cancer treatments.

Northwest Biotherapeutics announced a strategic reorganization of its US operations in October 2026, aimed at supporting the expansion of its DCVax® personalized immune therapy platform for solid tumors. The company expanded its technical team while eliminating non-essential positions, resulting in a net increase in US headcount while maintaining consistent operating costs. The expansion focuses on two priority areas: scaling production capacity through US manufacturing restart to support existing UK operations, and preparing clinical trials beyond brain cancer indications. Key hires include a Quality Assurance and Regulatory Affairs Manager from Roswell Park Cancer Center, essential for cGMP manufacturing compliance; a Director of Information Technologies from Team Logic IT to oversee enterprise strategy and automation implementation; and a Manager of Investor Relations with 30 years of experience at major asset managers. These strategic additions position NWBio to accelerate manufacturing capabilities and clinical development while strengthening governance infrastructure critical for advancing its personalized cancer vaccine programs.

Glioblastoma, an aggressive primary brain tumor, relies on metabolic and immunological remodeling of its tumor microenvironment for progression and therapeutic resistance. Tumor-associated macrophages (TAMs), including resident microglia and infiltrating monocyte-derived macrophages, represent abundant immune populations within this environment. While microglia normally maintain central nervous system homeostasis through immune surveillance and phagocytosis, tumor-derived signals, hypoxia, and nutrient deprivation reprogram these cells toward immunosuppressive phenotypes that promote tumor growth and immune evasion. This review, authored by researchers at Northwestern University's Feinberg School of Medicine, examines TAM-B-cell interactions and their role in glioblastoma immunosuppression. Key findings demonstrate extensive bidirectional communication between TAMs and B cells, wherein macrophages regulate B-cell activation and antigen presentation while B cells influence macrophage polarization. Metabolic competition within the tumor microenvironment—characterized by glucose depletion, lactate accumulation, and hypoxia—impairs B-cell functions and promotes regulatory B-cell development, reinforcing immune suppression. The article synthesizes findings on microbial metabolic reprogramming and macrophage-B-cell crosstalk, offering insights into potential therapeutic interventions targeting these immunometabolic mechanisms.

MimiVax and Roswell Park Comprehensive Cancer Center have released results from the SURVIVE Phase IIb clinical trial testing SurVaxM, a novel cancer vaccine designed to treat newly diagnosed glioblastoma. The trial enrolled 233 evaluable patients across 11 US cancer centers beginning in 2022. While SurVaxM failed to meet statistical significance as a primary endpoint across the entire patient population, improving median overall survival to 22.8 months compared to 20.3 months for placebo, the vaccine demonstrated statistically significant benefits in a prespecified subgroup of patients aged 65 and under, achieving median overall survival of 24.2 months versus 20.2 months. This younger cohort also showed significant improvement in progression-free survival, with 44 percent alive without progression at 12 months compared to 24 percent on placebo. Notably, approximately 42 percent of treated patients 65 and under survived 30 months or longer, representing a doubling of survival compared to placebo. SurVaxM is a first-in-class, patented peptide-mimic immunotherapeutic targeting survivin, a cell-survival protein present in approximately 95 percent of glioblastomas. Given the limited progress in glioblastoma treatment over two decades, these findings represent a meaningful advancement and provide a compelling case for FDA approval discussions.

This multicenter study evaluates whether patient-derived tumor organoid (PDO) drug sensitivity testing can guide treatment selection for adults with refractory, unresectable, or metastatic tumors. Fresh tumor tissue or malignant effusion is collected to establish PDOs, which undergo dose-response testing against clinically available drugs. Treatment decisions combine organoid sensitivity results with multidisciplinary clinical judgment, following guideline-recommended dosing protocols. Tumor response is assessed using RECIST version 1.1, with monitoring for progression, survival, and safety outcomes. The study encompasses nine tumor-specific cohorts, including non-small cell lung cancer, small cell lung cancer, prostate cancer, colorectal cancer, gastric cancer, pancreatic cancer, bladder cancer, pancreatic cancer, and non-clear cell renal cell carcinoma. Participants with failed organoid cultures or results exceeding 28 days are excluded from observation. This research addresses the critical clinical need for personalized treatment strategies in patients exhausting standard therapeutic options, potentially improving outcomes by matching drugs to individual tumor biology and sensitivity profiles.

Researchers at The Wistar Institute have developed a combination therapy that addresses two critical obstacles to immunotherapy success in glioblastoma, the most aggressive primary brain cancer in adults. Published in Neuro-Oncology, the study demonstrates that simultaneously reprogramming immunosuppressive myeloid cells while enhancing cancer-fighting T cells effectively shrinks tumors and prevents recurrence. While immunotherapy succeeds across many cancer types, glioblastoma response rates remain below ten percent. The research team, led by Dr. Filippo Veglia, identified that glioblastoma tumors exploit myeloid cells to suppress immune response while functional T cells become exhausted and ineffective. Through cell-by-cell analysis, scientists discovered that tumor hypoxia, or oxygen starvation, drives myeloid cell immunosuppression. Using axitinib, a low-dose drug already approved for kidney cancer treatment, the team relieved hypoxia within tumors, prevented myeloid reprogramming, and increased T cell infiltration. This dual-targeting approach represents a significant advance in making immunotherapy viable for glioblastoma patients, potentially transforming outcomes for this devastating disease.

Dendritic cell-based vaccines represent a promising immunotherapeutic approach for cancer treatment, yet their clinical efficacy remains inconsistent across malignancies. This narrative review synthesized evidence from human studies published between 2000 and 2026, examining dendritic cell vaccines in melanoma, glioblastoma, and prostate cancer through a comprehensive PubMed literature search using terms including "Sipuleucel-T" and "DCVax-L." While dendritic cell vaccines generally demonstrated safety and successfully activated tumor-specific T-cell responses, clinical outcomes proved heterogeneous. In melanoma, immune activation occurred frequently but with limited clinical benefit. DCVax-L improved overall survival in glioblastoma patients, whereas Sipuleucel-T provided modest survival benefits in prostate cancer. However, the phase III VIABLE trial testing DCVAC/PCa failed to improve overall survival. Engineered and biomaterial-based vaccine platforms showed immunogenicity but inconsistent efficacy. The findings suggest that despite eliciting antitumor immune responses, dendritic cell vaccines require optimization through combination therapeutic strategies to achieve clinically meaningful survival improvements and overcome tumor heterogeneity and immune evasion mechanisms.

Selective degradation of the endoplasmic reticulum (ER; reticulophagy) is a type of autophagy involved in the removal of ER fragments. So far, amino acid starvation as well as ER stress have been described as inducers of reticulophagy, which in turn restores cellular energy levels and ER homeostasis. Here, we explored the autophagy-inducing mechanisms that underlie the autophagic cell death (ACD)-triggering compound loperamide (LOP) in glioblastoma cells. Interestingly, LOP triggers upregulation of the transcription factor ATF4, which is accompanied by the induction of additional ER stress markers. Notably, knockout of ATF4 significantly attenuated LOP-induced autophagy and ACD. Functionally, LOP also specifically induces the engulfment of large ER fragments within autophagosomes and lysosomes as determined by electron and fluorescence microscopy. LOP-induced reticulophagy and cell death are predominantly mediated through the reticulophagy receptor RETREG1/FAM134B and, to a lesser extent, TEX264, confirming that reticulophagy receptors can promote ACD. Strikingly, apart from triggering LOP-induced autophagy and ACD, ATF4 is also required for LOP-induced reticulophagy. These observations highlight a key role for ATF4, RETREG1 and TEX264 in response to LOP-induced ER stress, reticulophagy and ACD, and establish a novel mechanistic link between ER stress and reticulophagy, with possible implications for additional models of drug-induced ER stress.

In cell culture, loperamide, a drug commonly used against diarrhea, proves effective against glioblastoma cells. A research team has now unraveled the drug's mechanisms of action of cell death induction and - in doing so - has shown how this compound could help attack brain tumors that otherwise are difficult to treat.

Oncolytic virotherapy represents a promising immunotherapeutic approach for cancer treatment that harnesses engineered or naturally occurring viruses to selectively destroy malignant cells while stimulating anti-tumor immune responses. This comprehensive review, published in October 2026 in Clinical and Experimental Medicine, examines the biological mechanisms underlying oncolytic virus function, including direct tumor cell lysis and immune system activation. The article synthesizes recent clinical advances demonstrating the efficacy of various oncolytic virus platforms in treating diverse cancer types, while addressing key challenges in optimizing viral delivery and overcoming tumor microenvironment barriers. The review discusses emerging strategies to enhance therapeutic potency through viral engineering and combination approaches with conventional therapies. By presenting current evidence and future research directions, this open-access publication provides clinicians and researchers with essential insights into the translational potential of oncolytic virotherapy, positioning it as an increasingly viable treatment modality within the evolving cancer care landscape alongside conventional chemotherapy and immunotherapy options.

I appreciate your request, but I notice that while you've provided the article title and publication metadata, the actual article content needed to write a comprehensive summary is not included in your message. You've shared the header information (title, journal name, publication date of October 8, 2026) but not the body text that would contain the context, methodology, findings, and conclusions. To provide an accurate and informative 150-word summary covering the entire article as you've requested, I would need the full article text. Could you please share the complete article content? Once you provide the body of the article, I'll be happy to deliver a professional summary suitable for an intelligence platform, including specific techniques, devices, molecules, or trial names mentioned, along with the key findings and their significance.

Glioblastoma multiforme remains one of oncology's most challenging malignancies, with median overall survival stubbornly hovering around fifteen months despite aggressive surgical resection, radiotherapy, and temozolomide chemotherapy. A comprehensive research perspective published in Oncoscience in September 2026 by Mamunur Rahman of East West University examines the evolving investigational landscape and concludes that the glioblastoma pipeline is undergoing fundamental transformation characterized by mechanistic breadth and biological sophistication. The article organizes emerging therapies into four mechanism-based domains: molecular-targeted therapies, immunotherapies and vaccines, oncolytic viruses and gene therapies, and agents targeting tumor metabolism and microenvironment. Critically, the field is shifting away from treating glioblastoma as a uniform disease toward biomarker-guided approaches that match treatments to individual tumor profiles. Patient selection increasingly relies on biomarkers including MGMT promoter methylation, IDH mutation status, EGFR amplification, and BRAF V600E alterations—defining biologically distinct patient groups. This stratification strategy mirrors successful paradigms established in lung cancer, breast cancer, and melanoma, offering renewed hope for improving outcomes in this historically refractory disease.